Newbridge Financial Services Group Inc. Sells 545 Shares of Danaher Co. (NYSE:DHR)

Newbridge Financial Services Group Inc. decreased its position in shares of Danaher Co. (NYSE:DHR) by 27.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,418 shares of the conglomerate’s stock after selling 545 shares during the quarter. Newbridge Financial Services Group Inc.’s holdings in Danaher were worth $328,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Cape Investment Advisory Inc. purchased a new stake in Danaher in the 4th quarter worth $25,000. BKM Wealth Management LLC purchased a new position in shares of Danaher in the 4th quarter valued at approximately $27,000. Wetzel Investment Advisors Inc. purchased a new stake in Danaher during the 4th quarter worth approximately $29,000. Rakuten Securities Inc. purchased a new position in Danaher in the 4th quarter worth $36,000. Finally, Financial Connections Group Inc. purchased a new stake in Danaher in the fourth quarter valued at approximately $41,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

DHR traded up $2.76 on Tuesday, reaching $256.89. 525,295 shares of the company’s stock were exchanged, compared to its average volume of 2,757,696. The stock’s fifty day moving average price is $253.68 and its 200-day moving average price is $244.68. The stock has a market cap of $190.28 billion, a PE ratio of 43.07, a P/E/G ratio of 3.90 and a beta of 0.85. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $269.11.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.36 earnings per share. Sell-side analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

Insider Activity

In other Danaher news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CFO Matthew Mcgrew sold 46,377 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $7,441,441.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 148,783 shares of company stock valued at $37,536,717. Company insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of several recent research reports. StockNews.com raised shares of Danaher from a “hold” rating to a “buy” rating in a report on Monday. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price objective for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Jefferies Financial Group initiated coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. TD Cowen raised their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Finally, Bank of America upped their price objective on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $269.29.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.